Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03521154 · ClinicalTrials.gov registry record · Phase 3

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

A Phase 3 study of Non-Small Cell Lung Cancer (Stage III), sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
216
Enrollment target
20
Study locations

NCT03521154 is a Phase 3 study of Non-Small Cell Lung Cancer (Stage III) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 216 participants, above the 67-participant average among 6 other Non-Small Cell Lung Cancer (Stage III) trials with a reported enrollment target (222% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03521154, a Phase 3 study of Non-Small Cell Lung Cancer (Stage III), is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
216 participants
Enrollment target
20
Study locations

Study Summary

A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer

Conditions Studied

Non-Small Cell Lung Cancer (Stage III)

Interventions

  • DRUG Osimertinib 80mg/40mg
  • DRUG Placebo Osimertinib 80mg/40mg

Study Locations (20)

Other

  • Research Site - Ciudad Autónoma de Bs. As.
  • Research Site - Ciudad Autónoma de Bs. As.
  • Research Site - Mar del Plata
  • Research Site - Rosario
  • Research Site - San Salvador de Jujuy
  • Research Site - Barretos
  • Research Site - Curitiba
  • Research Site - Florianópolis
  • Research Site - Fortaleza
  • Research Site - Porto Alegre
  • Research Site - Porto Alegre
  • Research Site - Ribeirão Preto
  • Research Site - São Paulo
  • Research Site - São Paulo
  • Research Site - Beijing

California

  • Research Site - Duarte

Georgia

  • Research Site - Atlanta

New Jersey

  • Research Site - Florham Park

Utah

  • Research Site - Salt Lake City

Wisconsin

  • Research Site - Madison

Trial Details

FieldValue
Enrollment Target 216 participants
Start Date 2018-07-19
Est. Completion 2027-04-13
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03521154

The ClinicalTrials.gov registry entry for NCT03521154 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 6 other Non-Small Cell Lung Cancer (Stage III) trials with a reported enrollment target (222% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer (Stage III) appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib 80mg/40mg is the first listed.

NCT03521154 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT03521154 about?

NCT03521154 is a clinical study titled "A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)". A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer

What is the current status of trial NCT03521154?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2018-07-19. Estimated completion is 2027-04-13.

What conditions does trial NCT03521154 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer (Stage III).

What interventions are being tested in trial NCT03521154?

The interventions under investigation include: Osimertinib 80mg/40mg (DRUG), Placebo Osimertinib 80mg/40mg (DRUG).

Who is sponsoring clinical trial NCT03521154?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03521154 being conducted?

This trial has 20 study locations across California, Georgia, New Jersey, Utah, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer (Stage III)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer (Stage III)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.